Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Completed 39Terminated 19Unknown 13Recruiting 6Active not recruiting 3Withdrawn 2Not yet recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

CNS 19Sarcoma 6Other solid neoplasm 2Genitourinary 2Gastrointestinal 2Endocrine 2Dermatologic 2Thoracic 1NET 1Lymphoid 1Gynecologic 1

Conditions

Zollinger-Ellison Syndrome 1Vipoma 1Somatostatinoma 1Pheochromocytoma 1Non functioning pancreatic endocrine tumor 1Neuroendocrine Tumors 1Multiple Endocrine Neoplasia Type 2b 1Multiple Endocrine Neoplasia Type 2a 1Multiple Endocrine Neoplasia Type 1 1Melanoma 1Insulinoma 1Glucagonoma 1Carcinoma, Merkel Cell 1Carcinoma, Medullary 1Carcinoid Tumor 1Brain Neoplasms 1Adrenal Cortex Neoplasms 1

Interventions

Nivolumab 18Ipilimumab 16pembrolizumab 15Cyclophosphamide 13trametinib 9Radiotherapy 8dabrafenib 6Interleukin-2 6sargramostim 5fludarabine phosphate 5aldesleukin 5Vemurafenib 5Peripheral Blood Stem Cell Transplantation 5Fluorouracil 5130-nm albumin-bound paclitaxel 5fludarabine 4Radiosurgery 4Melphalan 4Celecoxib 4encorafenib 3durvalumab 3binimetinib 3avelumab 3Vorinostat 3Specimen Handling 3Magnetic Resonance Spectroscopy 3Leucovorin 3Granulocyte-Macrophage Colony-Stimulating Factor 3Cytarabine 3Capecitabine 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Withdrawn × Temozolomide × Dermatologic × Clear all
NCT02831179 2017-09-28

Veliparib, Capecitabine, and Temozolomide in Patients With Advanced, Metastatic, and Recurrent Neuroendocrine Tumor

Vanderbilt-Ingram Cancer Center

Phase 1 Withdrawn
DermatologicEndocrineGastrointestinalNET

Non functioning pancreatic endocrine tumor, Adrenal Cortex Neoplasms, Carcinoid Tumor, Vipoma, Glucagonoma, Insulinoma, Pheochromocytoma, Somatostatinoma, Zollinger-Ellison Syndrome, Carcinoma, Merkel Cell, Carcinoma, Medullary, Neuroendocrine Tumors, Multiple Endocrine Neoplasia Type 1, Multiple Endocrine Neoplasia Type 2a, Multiple Endocrine Neoplasia Type 2b

NCT02065466 2016-04-21

Combo of Abraxane, TMZ, Bevacizumab in Metastatic Melanoma With Brain Metastases

University of Arizona

Phase 1/2 Withdrawn
CNSDermatologic

Brain Neoplasms, Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡